Royal Bank of Canada Reiterates Outperform Rating for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJGet Free Report)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank of Canada in a report released on Monday, Benzinga reports. They presently have a $175.00 price target on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 20.15% from the company’s current price.

A number of other brokerages have also issued reports on JNJ. lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, May 6th. Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to, the stock currently has a consensus rating of “Hold” and a consensus price target of $174.07.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE:JNJ opened at $145.65 on Monday. The stock has a market capitalization of $350.53 billion, a price-to-earnings ratio of 9.08, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company’s fifty day moving average is $148.13 and its two-hundred day moving average is $154.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.68 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.63 EPS for the current year.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently modified their holdings of the company. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson during the first quarter worth $31,000. Keener Financial Planning LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $40,000. WFA Asset Management Corp lifted its position in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $45,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.